INSTRUCTIONS Breast cancer: Overview and updates
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 27. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $21.95 to: Lippincott Williams & Wilkins, CE Group, 2710 Yorktowne Blvd., Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is December 31, 2013.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1–800–787–8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.4 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.4 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454.
Your certificate is valid in all states. This activity has been assigned 1.5 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Breast cancer: Overview and updates
General Purpose: To provide the nurse practitioner (NP) with an overview of the current treatment of BC. Learning Objectives: After reading this article and taking this test, the NP will be able to: 1. Describe the pathology and staging of BC and local treatment control via surgery and radiation therapy. 2. Discuss pharmacologic strategies for treating BC. 3. Identify BC follow-up and risk reduction strategies for primary BC.
1. Which type of BC is stage 0, noninvasive, and has an excellent prognosis?
d. IBC with squamous features
2. Using the Bloom Richardson scale, which grade is given to tumors with poorly differentiated histologic features?
a. Grade I
b. Grade II
c. Grade III
d. Grade IV
3. One of the best indicators for overall survival of BC is
a. the histology grade.
b. axillary lymph node involvement.
c. tumor size.
d. tumor location.
4. BC tumor stage is determined by all except
a. tumor size.
b. presence or absence of metastatic disease.
c. extent of nodal involvement.
d. tumor location.
5. Patients with BRCA1 are more likely to develop tumors that are
a. ER positive.
b. PARP negative.
c. Her-2/neu positive.
d. ER/PR/Her-2/neu negative.
6. The NCCN considers margins to be clear if normal tissue between the tumor and the surgical margin measures at least
a. 0.5 mm.
b. 1 mm.
c. 1.5 mm.
d. 2 mm.
7. Following lumpectomy, standard whole breast radiation therapy consists of which regimen followed by a 1-week boost to the site?
a. 3 days per week for 8 weeks
b. 4 days per week for 6 weeks
c. 5 days per week for 5 weeks
d. 6 days per week for 6 weeks
8. Before initiating chemotherapy, a staging workup for suspected metastatic disease should be done including all except
a. bone marrow biopsy.
b. bone scan.
c. CT scan of the abdomen and pelvis.
d. CT scan of the chest.
9. ER-positive and PR-positive tumors benefit from
a. radiation therapy alone.
b. chemotherapy alone.
c. radiation and chemotherapy.
d. endocrine therapy.
10. A premenopausal patient with DCIS is a candidate for which of the following hormonal agents?
11. Postmenopausal women with hormone receptor positive IBC may receive the most benefit from which drug?
12. The recommended dosage of fulvestrant for patients without hepatic impairment is
a. 250 mg.
b. 500 mg.
c. 750 mg.
d. 1,000 mg.
13. A common adverse reaction of eribulin mesylate is
b. chest pain.
14. Compared to zoledronic acid, denosumab has a slightly higher risk of
15. After the last breast conservation surgery, when should the patient have a mammogram on the affected breast?
a. 3 months, then 3 months later
b. 6 months, then 6 months later
c. 6 months, then 1 year later
d. 1 year, then every 2 years later
16. Lifestyle recommendations for women with BC should include all except
a. getting regular exercise.
b. drinking fewer than 3 alcoholic drinks per week.
c. losing weight if BMI indicates overweight.
d. eliminating caffeine.
17. Known BRCA1 or BRCA2 genetic mutations place women at how much increased risk of BC in their lifetimes?
a. up to 20%
b. 20 to 30%
c. 40 to 50%
d. 60 to 80%
© 2011 Lippincott Williams & Wilkins, Inc.